294 related articles for article (PubMed ID: 24866769)
21. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
22. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.
Chen H; Pan H; Qian Y; Zhou W; Liu X
Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680
[TBL] [Abstract][Full Text] [Related]
23. MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression.
Kuo WH; Chu PY; Wang CC; Huang PS; Chan SH
Biol Direct; 2023 Aug; 18(1):44. PubMed ID: 37550720
[TBL] [Abstract][Full Text] [Related]
24. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
25. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
26. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
Qian J; Ma Y; Tahaney WM; Moyer CL; Lanier A; Hill J; Coleman D; Koupaei N; Hilsenbeck SG; Savage MI; Page BDG; Mazumdar A; Brown PH
Breast Cancer Res; 2024 Feb; 26(1):23. PubMed ID: 38317231
[TBL] [Abstract][Full Text] [Related]
27. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
28. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
29. Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells.
Wen Y; Dai G; Wang L; Fu K; Zuo S
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30842344
[TBL] [Abstract][Full Text] [Related]
30. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
House CD; Grajales V; Ozaki M; Jordan E; Wubneh H; Kimble DC; James JM; Kim MK; Annunziata CM
BMC Cancer; 2018 May; 18(1):595. PubMed ID: 29801480
[TBL] [Abstract][Full Text] [Related]
31. CCAAT-displacement protein/cut homeobox transcription factor (CUX1) represses estrogen receptor-alpha (ER-α) in triple-negative breast cancer cells and can be antagonized by muscadine grape skin extract (MSKE).
Burton LJ; Hawsawi O; Sweeney J; Bowen N; Hudson T; Odero-Marah V
PLoS One; 2019; 14(4):e0214844. PubMed ID: 30964885
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
[TBL] [Abstract][Full Text] [Related]
33. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
[TBL] [Abstract][Full Text] [Related]
34. Lentiviral vector-mediated doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative breast cancer cells.
Liu S; Liu X; Wang H; Zhou Q; Liang Y; Sui A; Yao R; Zhao B; Sun M
Oncol Rep; 2015 May; 33(5):2477-83. PubMed ID: 25812575
[TBL] [Abstract][Full Text] [Related]
35. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression.
Zhang X; Zhou Y; Mao F; Lin Y; Shen S; Sun Q
Sci Rep; 2020 May; 10(1):7662. PubMed ID: 32376943
[TBL] [Abstract][Full Text] [Related]
36. Circular RNA circ-ZEB1 acts as an oncogene in triple negative breast cancer via sponging miR-448.
Pei X; Zhang Y; Wang X; Xue B; Sun M; Li H
Int J Biochem Cell Biol; 2020 Sep; 126():105798. PubMed ID: 32629026
[TBL] [Abstract][Full Text] [Related]
37. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
38. hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.
Park S; Sung Y; Jeong J; Choi M; Lee J; Kwon W; Jang S; Park SJ; Kim HS; Lee MH; Kim DJ; Liu K; Kim SH; Dong Z; Ryoo ZY; Kim MO
Oncotarget; 2017 Jun; 8(23):37115-37127. PubMed ID: 28415749
[TBL] [Abstract][Full Text] [Related]
39. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.
Dutta P; Sarkissyan M; Paico K; Wu Y; Vadgama JV
Breast Cancer Res Treat; 2018 Aug; 170(3):477-486. PubMed ID: 29594759
[TBL] [Abstract][Full Text] [Related]
40. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
